Scholars Central

Research articlePublished 29 Aug 2022

Drug Target of Protein and Diabetic Nephropathy

Authors: Azka Khan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In biomedical research, the discovery and validation of drug targets are essential, and numerous studies have been done to analyse drug target properties in order to better understand the fundamentals of their actions. However, the majority of them are based on either solid biological assumptions or the distinct chemical and physical characteristics of those targets. In this study, we evaluated three major approaches to understanding functional biomolecules based on the topological characteristics of pharmacological targets. The protein-protein interactions network shows no discernible distinctions between targets and common proteins, indicating the drug targets are neither the bridge proteins nor the dominating hub proteins. There are notable distinctions between known targets and other proteins based on some unique topological structures of the pharmacological targets. There are notable distinctions between the known targets and other proteins based on certain unique topological structures of the pharmacological targets. Additionally, based on their modularity, the pharmacological targets primarily belong to three types of communities. These topological characteristics can be used to better understand how the PPI network's drug targets function. In particular, it is a different approach to extract no targets or anticipate possible targets to test a new therapeutic target quickly and affordably. In this manner, the homologous set of a pharmacological target, which contains 102 possible target proteins, is predicted in the article. People with diabetic nephropathy (DN) have a lower quality of life and a shorter life expectancy. Evidence suggests that interactions between activated protein kinase C (PKC), advanced glycation end products (AGEs), and angiotensin II worsen the course of DN. A number of drugs have been studied to see if they can reduce the progression of DN, including AGEs, PKC, renin-angiotensin-aldosterone system (RAAS), and angiotensin-converting enzyme (ACEI) inhibitors. It is unclear whether specific molecular targets of drugs cause an improvement in renal damage in DN. In this review, the prospective treatment targets are outlined based on hypothesised illness progression mechanisms.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Drug Development and Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Drug Development and Research
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Azka Khan”